Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of hematology 2020-11, Vol.99 (11), p.2565-2576
Hauptverfasser:	Bekoz, Huseyin, Ozbalak, Murat, Karadurmus, Nuri, Paydas, Semra, Turker, Alev, Toptas, Tayfur, Tuglular, Tülin Firatli, Altuntas, Fevzi, Cakar, Merih Kizil, Sonmez, Mehmet, Gulbas, Zafer, Demir, Nazlı, Kaynar, Leylagul, Yildirim, Rahsan, Karadogan, Ihsan, Arat, Mutlu, Kapucu, Irem, Aslan, Nevin Alayvaz, Ozkocaman, Vildan, Turgut, Mehmet, Yuksel, Meltem Kurt, Ozcan, Muhit, Hacioglu, Sibel Kabukcu, Barista, Ibrahim, Demirkaya, Metin, Saydam, Guray, Toprak, Selami K., Yilmaz, Mehmet, Demirkol, Onur, Ferhanoglu, Burhan
Format:	Artikel
Sprache:	eng
Schlagworte:	Hematology Medicine Medicine & Public Health Oncology Original Article
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!